Nomura Securities analyst Shibani Malhotra sees compelling risk/reward in Pacira Pharmaceuticals (NASDAQ: PCRX) ahead of PI decision. The firm reiterated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE